Biodegradable hollow mesoporous organosilica nanotheranostics (HMONs) as a versatile platform for multimodal imaging and phototherapeutic-triggered endolysosomal disruption in ovarian cancer. (31st December 2022)

• Record Type: Journal Article
• Authors: Li, Pengfei; Lin, Bingquan; Chen, Zhian; Liu, Pan; Liu, Jiaqi; Li, Weili; Liu, Ping; Guo, Zhaoze; Chen, Chunlin
• Is Part Of: Drug delivery. Volume 29:Number 1(2022)
• Page Start: 161
• Page End: 173
• Publication Date: 2022-12-31
• Subjects: Hollow mesoporous organosilica nanoparticles (HMONs) -- ovarian cancer -- multimodal imaging -- phototherapy -- lysosomal disruption; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2021.2021322
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: A major impediment in the development of nanoplatform-based ovarian cancer therapy is endo/lysosome entrapment. To solve this dilemma, a hollow mesoporous organosilica-based nanoplatform (HMON@CuS/Gd2 O3 ) with a mild-temperature photothermal therapeutic effect and multimodal imaging abilities was successfully synthesized. HMON@CuS/Gd2 O3 exhibited an appropriate size distribution, L-glutathione (GSH)-responsive degradable properties, and high singlet oxygen generation characteristics. In this study, the nanoplatform specifically entered SKOV-3 cells and was entrapped in endo/lysosomes. With a mild near infrared (NIR) power density (.5 W/cm 2 ), the HMON@CuS/Gd2 O3 nanoplatform caused lysosome vacuolation, disrupted the lysosomal membrane integrity, and exerted antitumour effects in ovarian cancer. Additionally, our in vivo experiments indicated that HMON@CuS/Gd2 O3 has enhanced T1 MR imaging, fluorescence (FL) imaging (wrapping fluorescent agent), and infrared thermal (IRT) imaging capacities. Using FL/MRI/IRT imaging, HMON@CuS/Gd2 O3 selectively caused mild phototherapy in the cancer region, efficiently inhibiting the growth of ovarian cancer without systemic toxicity in vivo . Taken together, the results showed that these well-synthesized nanoplatforms are likely promising anticancer agents to treat ovarian cancer and show great potential for biomedical applications.